The CD59 Knockout NCI-H1299 Polyclonal Cells product is a ready-to-use polyclonal knockout cell population generated by CRISPR/Cas9-mediated gene disruption of CD59 in the NCI-H1299 human non-small cell lung carcinoma cell line. This polyclonal pool preserves genetic diversity and avoids artefactual phenotypes associated with single-cell cloning, making it suitable for studying CD59 function in a bulk cancer cell setting.
The host NCI-H1299 line originates from a lymph node metastasis of a non-small cell lung carcinoma and is a widely used model for lung adenocarcinoma research. These adherent epithelial cells harbor a homozygous deletion of the TP53 gene, rendering them p53-null, which abolishes p53-dependent apoptosis and cell cycle control. Their derivation from a metastatic site and p53 deficiency make them particularly suitable for investigating invasion, migration, and chemoresistance mechanisms in lung cancer.
CD59 encodes a glycosylphosphatidylinositol (GPI)-anchored complement regulatory protein that binds to the C8?? subunit of the nascent membrane attack complex (MAC) and prevents C9 recruitment and polymerization, thereby blocking cytolytic pore formation. CD59 expression is upregulated by inflammatory cytokines including TNF-??, IL-1??, and IFN-??, often via NF-??B-mediated transcriptional activation. Its protective activity directly counteracts complement-mediated lysis by inhibiting C5b-9 assembly, but CD59 also modulates T cell activation by interacting with CD2 and promoting lipid raft-associated signaling through Src family kinases Lck and Fyn. Consequently, CD59 links innate complement defense with adaptive immune co-stimulation, and its loss reshapes downstream activation of integrin LFA-1.
Disruption of CD59 in NCI-H1299 cells abrogates the major complement defense mechanism of these cancer cells, rendering them susceptible to complement-dependent cytotoxicity triggered by therapeutic antibodies or human serum. This knockout model is thus a powerful tool for dissecting complement-mediated tumor cell lysis, immune evasion strategies employed by non-small cell lung cancer, and the interplay between complement regulation and T cell co-stimulation. Given the p53-null background, it also permits examination of CD59 function independently of p53-driven apoptosis or stress responses.
Researchers can employ these CD59 knockout polyclonal NCI-H1299 cells in a range of experimental workflows, including complement-mediated lysis assays using human serum, immunofluorescence detection of C5b-9 MAC deposition, flow cytometric verification of CD59 loss, western blot analysis, and antibody-dependent cell-mediated cytotoxicity (ADCC) experiments. The model further supports examination of T cell co-stimulation through measurement of IL-2 secretion and can be adapted for high-throughput screening of complement inhibitors. For ordering or technical inquiries, please contact Ascent Research.
